It can help the quality of your life. While there has been improvement in the treatment of asthma, indications are that the improvement has been due to earlier identification of the condition, and the wide spread use of inhaled corticosteroids. Asthma can be seen as either a mild, moderate or severe disease. Each calls for a different approach to its treatment. Mild asthma is usually controlled by use of low dosages of corticosteroid inhalers.
Moderate asthma is treated with adding a long-acting beta agonist or a low dose of theophylline.
The severe cases may require high doses of corticosteroid inhalers or oral corticosteroid, the long-term use of which is associated with adverse side effects. An antibody is injected into the body and is believed to suppress the late-phase reaction of asthma, which is associated with bronchial inflammation followed by bronchococonstriction. It is a recombinant humanized monoclonal antibody called rhuMAb-E25. Henry Milgrom, M.D. and his group at The National Jewish Medical and Research Center as well as other sites throughout the country carried out this study. It would drastically reduce the need for bronchodilators as a rescue medication.